Natera has begun the subject enrolment in the randomised Phase III SAGITTARIUS clinical trial designed to assess the ...

Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. RSI readings suggest the stock ...

Natera (NTRA) announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Natera (NTRA) to $200 from $160 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

Natera, Inc.（纳斯达克股票代码：NTRA）的董事Chapman Rowan ...

德克萨斯州奥斯汀讯——根据向美国证券交易委员会提交的4表格显示，Natera, Inc.（纳斯达克股票代码：NTRA）临床诊断总裁Solomon Moshkevich最近进行了一笔重大的公司股票交易。Moshkevich于2024年12月9日以加权平均价格166.5937美元每股的价格出售了4,858股Natera普通股。此次出售的总价值约为809,312美元。根据 InvestingPro ...

Cross-ancestry polygenic risk score now offered with the Empower™ hereditary cancer test AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling company, today announced the launch ...

The full terms of the agreement will be disclosed in Natera's annual report on Form 10-K for the year ending December 31, 2024. This announcement is based on a press release statement and provides ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling ...